Biodexa Pharmaceuticals Plc (BDRX)

The investment case for this biotechnology firm is effectively extinguished by a decade of catastrophic capital destruction. While the company recently executed a massive 10,000-to-1 reverse split to keep the share price accessible, the underlying economics tell a grim story: the stock has lost virtually all of its value over the last nine years, with every single annual period showing a double-digit percentage decline. This is not a temporary correction; it is a structural implosion where the market has repeatedly rejected the business model, driving the price from hundreds of millions of dollars to pennies. Fundamentally, the company is bleeding cash, reporting negative returns on both assets and equity, and burning through operating cash flow with no visible path to profitability. The balance sheet, while currently debt-light, cannot sustain operations without external financing, which is unlikely given the lack of investor appetite. There is no dividend to provide income, and the recent price action shows no signs of stabilization, merely hovering near historic lows. Any hope of a turnaround is currently outweighed by the sheer magnitude of the historical decline and the ongoing operational hemorrhage.